Overview
Medivir, the Swedish pharmaceuticals developer trading under MVIR, announced results for the first quarter showing a modest uptick in revenue alongside an improved EBITDA position, and confirmed completion of a financing round intended to underpin its clinical programs.
Quarterly financials
For the quarter, the company recorded revenue of SEK 1 million. EBITDA losses narrowed to SEK 8.80 million compared with prior periods. Adjusted free cash flow for the reporting period was negative SEK 13 million. At the end of the quarter Medivir reported cash and cash equivalents of SEK 149.1 million.
Financing and corporate comment
In February Medivir completed a directed share issue raising SEK 45 million. CEO Jens Lindberg said the transaction strengthened the company's financial position and enabled continued clinical development of MIV-711.
Clinical development plans
The company plans to initiate a phase 2 proof-of-concept study for MIV-711 in Osteogenesis Imperfecta. In addition, a randomized study of fostrox in second-line liver cancer is scheduled to begin. Lindberg noted that the start-up and preparatory work for the MIV-711 and fostrox clinical programs have advanced the project portfolio.
Pipeline timing
Medivir expects results from an ongoing veterinary study of MIV-701 in the fourth quarter of 2026.
Implications for investors and sector observers
The figures underscore a company still operating with a small revenue base and negative cash flow, but with strengthened liquidity following the SEK 45 million share issue. The updates on study starts and the veterinary data timeline provide defined milestones for stakeholders tracking clinical progress.
Conclusion
Medivir's Q1 report combines modest operational revenue with an improving EBITDA trajectory and bolstered cash resources, while the firm advances multiple clinical programs with forthcoming milestones into 2026.